Across TCGA pan-cancer cohorts, PHF2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PHF2 data layer compared with 21 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher PHF2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PHF2 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

LUSC, LUAD, and ESCA are the cancer types where PHF2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	II,III,IV	0.181	0.742	.032	12	view →
LUAD	OS	Median	All	0.422	0.701	.021	4	view →
ESCA	DFS	Median	All	0.162	0.506	.022	3	view →
SKCM	DFS	Median	II,III,IV	0.878	0.559	.027	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: PHF2 tumor-vs-normal RNA expression · all PHF2 data types